Prospective, observational real-life study on eligibility for and outcomes of antiviral treatment with peginterferon α plus ribavirin in chronic hepatitis C

Noninvasive Assessment of Liver Fibrosis By Transient Elastography and FIB4/APRI for Prediction of Treatment Response in Chronic Hepatitis C—An Experience from a Tertiary Care Hospital

“…This may be explained by the fact that higher age is often accompanied by concomitant diseases (psychiatric, vascular and metabolic, including insulin resistance and diabetes mellitus) or cirrhosis that makes IFN-based antiviral treatment more difficult to tolerate due to side effects. 31 Our study also showed lower response rates to treatment in patients having history of significant alcohol intake and higher fibrosis levels which are in accordance with previous studies. 32 The SVR rates were significantly higher in patients without cirrhosis (LSM < 12.5 kPa) as compared to those with cirrhosis (LSM !…”

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY‐3+)

“…The combination of SOF plus RBV (SOF‐RBV) requires a 24‐week treatment duration, and SVR rates are suboptimal among patients with previous treatment experience and/or cirrhosis . This response rate can be improved by the addition of Peg‐IFN‐α to SOF‐RBV (SOF‐RBV‐Peg‐IFN‐α), though at the expense of introducing a significant burden of interferon‐associated adverse events (AEs) that excludes a large proportion of individuals who are unwilling or unable to take interferons …”

“…(22)(23)(24)(25) This response rate can be improved by the addition of Peg-IFN-a to SOF-RBV (SOF-RBV-Peg-IFN-a), (22,26) though at the expense of introducing a significant burden of interferon-associated adverse events (AEs) (27) that excludes a large proportion of individuals who are unwilling or unable to take interferons. (28)(29)(30) Daclatasvir (DCV), a pangenotypic nonstructural protein 5A (NS5A) inhibitor, (31) has picomolar activity against wild-type genotype 3. For patients without cirrhosis, RBV-free treatment with DCV plus SOF (DCV-SOF) for 12 weeks is highly effective for treatment of genotype 3 infection.…”